Day Zero Diagnostics inks new partnership for bloodstream infection diagnostics

Day Zero Diagnostics and Oxford Nanopore today announced a collaboration to develop a solution for diagnosing bloodstream infections.

Boston-based Day Zero Diagnostics develops diagnostics utilizing whole-genome sequencing and AI to combat antibiotic-resistant infections. Oxford Nanopore offers a new generation of nanopore-based molecular sensing technology. They seek to enable early detection to combat bloodstream infections as they are a leading cause of sepsis.

The companies plan to integrate and optimize a diagnostic system for use in clinical settings like hospitals. They aim to offer same-day identification and genomic-based antibiotic susceptibility profiling without the need for blood culture. According to a news release, the companies plan to pursue regulatory approvals, including with the FDA, down the line.

In the collaboration, the companies intend to combine Day Zero Diagnostics’ ultra-high enrichment sample preparation technology and …

Read more
  • 0

Day Zero Diagnostics completes $16M funding round

Day Zero Diagnostics — which seeks to harness whole-genome sequencing and AI in the fight against antibiotic-resistant infections — announced today that it has successfully wrapped up a $16M financing round.

The latest round raises the Boston-based company’s venture capital funding total to $49M, coupled with over $18M in non-dilutive funding.

“This funding is a strong vote of confidence in Day Zero Diagnostics’ potential to use rapid sequencing and AI to disrupt microbiology lab diagnostics,” Day Zero Diagnostics co-founder and CEO Jong Lee said in a news release.

“DZD is focused on bringing an FDA-cleared diagnostic to market that will deliver the ‘holy grail’ of infectious disease diagnostics – same-day organism identification and antimicrobial susceptibility profiling directly from clinical samples, and our investors share our belief in the game-changing nature of our technology.”

Day Zero Diagno…

Read more
  • 0

Day Zero Diagnostics raises $8.2M from CARB-X

Day Zero Diagnostics announced that it received an $8.2 million award in optional stage funding from CARB-X.

The infectious disease diagnostic developer received an initial $6.2 million CARB-X award in May 2020. CARB-X, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, aims to accelerate early antibacterial R&D. This would address the rising global threat of drug-resistant bacteria.

Day Zero’s total award funding now sits at more than $16 million. The company also completed a venture equity financing worth $21 million in February.

Anti-biotic-resistant infections remain on the rise. Worries persist that superbugs could eventually evolve to the point that antibiotics no longer work effectively. In 2020, more than 20 biopharmaceutical companies around the world pledged more than $1 billion toward the Antimicrobial Resistance (AMR) Action Fund.

Day Zero develops whole genome sequencing-based diagnostic technologies.…

Read more
  • 0

Day Zero Diagnostics raises $21M

Infectious disease diagnostic company Day Zero Diagnostics announced today that it completed a venture equity financing worth $21 million.

Sands Capital led the financing round, while significant participation came from new investors including BD, Panacea Venture and Hongkou Capital, along with existing investors including Triventures and Golden Seeds.

To date, Zero Day Diagnostics has raised more than $33 million in venture capital financing and more than $10 million in non-dilutive funding, according to a news release. In May 2020, the company received $6.2 million of that non-dilutive funding from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).

Boston-based Day Zero Diagnostics’ develops sequencing-based diagnostic technologies for identifying the species and antibiotic resistance profile of a bacterial pathogen within hours. The company’s approach aims to save lives while reducing the economic burden of…

Read more
  • 0